ArticleTomography (Ann Arbor, Mich.)2025
Dual-Stage AI Model for Enhanced CT Imaging: Precision Segmentation of Kidney and Tumors.
Article in Tomography (Ann Arbor, Mich.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Automated Renal Tumor Segmentation in Computed Tomography Images Using a Global Attention-Based DeepLabV3+ Model: Algorithm Development and Validation.JMIR medical informatics · 2026Article
- Automated model-based lesion tracking in CT: colorectal liver metastases as a use case for development and performance analysis.European radiology experimental · 2026Article
- The Evolving Role of Artificial Intelligence in Andrological Surgery: Current Landscape and Future Direction.Journal of clinical medicine · 2026Review
- Clinical-Oriented Hierarchical Machine Learning Framework for Early Kidney Tumor Detection and Malignant Subtype Classification.Tomography (Ann Arbor, Mich.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesAccurate kidney and tumor segmentation of computed tomography (CT) scans is vital for diagnosis and treatment, but manual methods are time-consuming and inconsistent, highlighting the value of AI automation. This study develops a fully automated AI model using vision transformers (ViTs) and convolutional neural networks (CNNs) to detect and segment kidneys and kidney tumors in Contrast-Enhanced (CECT) scans, with a focus on improving sensitivity for small, indistinct tumors.
methodsThe segmentation framework employs a ViT-based model for the kidney organ, followed by a 3D UNet model with enhanced connections and attention mechanisms for tumor detection and segmentation. Two CECT datasets were used: a public dataset (KiTS23: 489 scans) and a private institutional dataset (Private: 592 scans). The AI model was trained on 389 public scans, with validation performed on the remaining 100 scans and external validation performed on all 592 private scans. Tumors were categorized by TNM staging as small (≤4 cm) (KiTS23: 54%, Private: 41%), medium (>4 cm to ≤7 cm) (KiTS23: 24%, Private: 35%), and large (>7 cm) (KiTS23: 22%, Private: 24%) for detailed evaluation.
resultsKidney and kidney tumor segmentations were evaluated against manual annotations as the reference standard. The model achieved a Dice score of 0.97 ± 0.02 for kidney organ segmentation. For tumor detection and segmentation on the KiTS23 dataset, the sensitivities and average false-positive rates per patient were as follows: 0.90 and 0.23 for small tumors, 1.0 and 0.08 for medium tumors, and 0.96 and 0.04 for large tumors. The corresponding Dice scores were 0.84 ± 0.11, 0.89 ± 0.07, and 0.91 ± 0.06, respectively. External validation on the private data confirmed the model's effectiveness, achieving the following sensitivities and average false-positive rates per patient: 0.89 and 0.15 for small tumors, 0.99 and 0.03 for medium tumors, and 1.0 and 0.01 for large tumors. The corresponding Dice scores were 0.84 ± 0.08, 0.89 ± 0.08, and 0.92 ± 0.06.
conclusionsThe proposed model demonstrates consistent and robust performance in segmenting kidneys and kidney tumors of various sizes, with effective generalization to unseen data. This underscores the model's significant potential for clinical integration, offering enhanced diagnostic precision and reliability in radiological assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.